To the Editor Precision oncology offers thrilling therapeutic possibilities, as demonstrated by Cobain and colleagues1 in their cohort study. We do, however, have concerns regarding the generalizability of their findings, in particular, the expansive recommendation for “directed germline testing in all patients with advanced cancer.”1(p525)